CEO of WAVE Life Sciences, Paul Bolno, sold 48,366 shares at $5.78 each, totaling $279,575. WAVE focuses on genetic disease therapies. Insider transaction history shows more buying than selling. The stock is slightly overvalued according to GF Value.